COVID-19封锁期间美国联邦医疗保险参保者中社会经济脆弱性与罗莫索单抗骨质疏松治疗差异
研究纳入2019年4月至2020年9月启动罗莫索单抗的65岁以上女性联邦医疗保险参保者6777例,评估县级社会经济脆弱性与停药及封锁期间治疗重启的关联。结果显示较高社会经济水平与COVID-19封锁期间停药风险降低相关(调整HR=0.79),且停药后6个月内更可能重启治疗(调整HR=1.14),主要驱动于换药(调整HR=1.30)。
核心结论
- 生活在较高社会经济水平(较低脆弱性)县的联邦医疗保险参保者在COVID-19封锁期间较少停用罗莫索单抗,若停药则更可能换药,导致治疗间隙更短。
- 作者认为,在未来突发公共卫生事件中为脆弱患者提供及时支持对维持治疗依从性至关重要。
研究设计与样本
- 研究纳入2019年4月至2020年9月启动罗莫索单抗的65岁及以上女性联邦医疗保险参保者,共6777例新使用者。
- 停药定义为两次给药间隔超过60天;社会经济脆弱性采用县级社会脆弱性指数社会经济主题评估;计算停药风险评分以控制个体特征;采用Cox比例风险模型评估县级社会经济水平与停药的关联;二次分析考察停药后6个月内治疗重启。
主要发现
- 2937例停药患者中,1816例在6个月内重启骨质疏松治疗,其中661例换用其他药物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Higher area socioeconomic level was associated with a decreased risk of romosozumab discontinuation during COVID-19 lockdown among U.S. Medicare beneficiaries. Patients in these areas were more likely to restart osteoporosis treatment post-discontinuation. Timely support for vulnerable patients is crucial for improving adherence during public health crises. PURPOSE: To evaluate the association between area socioeconomic (SES) vulnerability and the discontinuation of romosozumab and the impact of the COVID lockdown on osteoporosis treatment among women enrolled in the U.S. Medicare who initiated romosozumab. METHODS: Female Medicare beneficiaries aged 65 and older who initiated romosozumab between April 2019 and September 2020 were included. Discontinuation was defined as a > 60-day gap between doses. SES vulnerability was assessed using the county-level Social Vulnerability Index SES theme. A Discontinuation Risk Score (DcRS) was calculated to control for individual characteristics. A Cox proportional hazards model evaluated the association between county SES and discontinuation. Secondary analyses examined treatment restart within six months post-discontinuation. RESULTS: The study included 6,777 new romosozumab users. Higher area SES level (lower vulnerability) was associated with a reduced risk of discontinuation during the COVID-19 lockdown (adjusted HR = 0.79 [0.68, 0.92] for the highest vs. lowest SES). Of 2,937 patients who discontinued, 1,816 restarted osteoporosis treatments within 6 months, including 661 switching to other medications. Patients in the highest SES group were more likely to restart osteoporosis treatment during lockdown (adjusted HR = 1.14 [1.01-1.30]) comparing with the lowest SES group, which is primarily driven by treatment switch (adjusted HR = 1.30 [1.06-1.60]). CONCLUSION: Medicare beneficiaries in counties with higher SES level (lower vulnerability) were less likely to discontinue romosozumab during the COVID-19 lockdown and more likely to switch treatments if discontinued, resulting in shorter treatment gaps. Providing timely support to vulnerable patients is vital for maintaining treatment adherence during future public health emergencies.
引用
- Liu Y, Arora T, Zhang J, et al. Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab. Osteoporos Int. 2025. PMID: 40920190. doi:10.1007/s00198-025-07677-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。